U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H23NO
Molecular Weight 269.3813
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIFEMELANE

SMILES

CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2

InChI

InChIKey=QSQQPMHPCBLLGX-UHFFFAOYSA-N
InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3

HIDE SMILES / InChI
Molecular Formula C18H23NO
Molecular Weight 269.3813
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://drug.mynahcare.com/drugs/genericdetail/bifemelane-Mjg1 | https://www.ncbi.nlm.nih.gov/pubmed/8846747 | https://www.ncbi.nlm.nih.gov/pubmed/8851457 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/8474231 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/7490169

Bifemelane is a psychotropic drug, was found to inhibit monoamine oxidase (MAO). It inhibited type A MAO (MAO-A) competitively and type B (MAO-B) noncompetitively and it was a more potent inhibitor of MAO-A than of MAO-B. Bifemelane is an antidepressant and cerebral activator that is used in Japan for the treatment of cerebral infarction patients with depressive symptoms, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.

CNS Activity

Originator

Mitsubishi Chemical
14
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7186825

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 4.2 µM [Ki]
Inhibitor
8297
 46.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
BIFEMELANE

Approved Use

BIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.
Primary
Approved
8429
BIFEMELANE

Approved Use

BIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.
Primary
Approved
8429
BIFEMELANE

Approved Use

BIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.
Primary
Approved
8429
BIFEMELANE

Approved Use

BIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.
PubMed

PubMed

TitleDatePubMed
4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.
1988 Jan
The clinical effect of bifemelane hydrochloride on dementia in aged patients.
1991
Patents

Patents

JP2011526251A
112
US5547993A
2
US6036973A
2

Sample Use Guides

In Vivo Use Guide
150 mg daily in divided doses.
Route of Administration: Oral
In Vitro Use Guide
Bifemelane 10 nM to 1 uM significantly augmented the long-term potentiation in the CA3 region of guinea pig hippocampal slices
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:00:55 GMT 2023
Edited
by admin
on Sat Dec 16 18:00:55 GMT 2023
Record UNII
Z4501GN13G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIFEMELANE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
N-METHYL-4-((.ALPHA.-PHENYL-O-TOLYL)OXY)BUTYLAMINE
Common Name English
bifemelane [INN]
Common Name English
4-(2-BENZYLPHENOXY)-N-METHYLBUTAN-1-AMINE
Systematic Name English
BIFEMELANE [MART.]
Common Name English
Bifemelane [WHO-DD]
Common Name English
2-(4-METHYLAMINOBUTOXY)DIPHENYLMETHANE
Common Name English
4-(O-BENZYLPHENOXY)-N-METHYLBUTYLAMINE
Common Name English
N-METHYL-4-(2-(PHENYLMETHYL)PHENOXY)-1-BUTANAMINE
Systematic Name English
4-(2-BENZYLPHENOXY)-N-METHYLBUTYLAMINE
Systematic Name English
1-BUTANAMINE, N-METHYL-4-(2-(PHENYLMETHYL)PHENOXY)-
Systematic Name English
BIFEMELANE [MI]
Common Name English
2-BENZYL-1-(4-(METHYLAMINO)BUTOXY)BENZENE
Systematic Name English
Classification Tree Code System Code
WHO-ATC N06AX08
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
WHO-VATC QN06AX08
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
Code System Code Type Description
DRUG BANK
DB13550
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045663
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
FDA UNII
Z4501GN13G
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
MERCK INDEX
m2480
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1192517
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
INN
5902
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
SMS_ID
100000085883
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
WIKIPEDIA
BIFEMELANE
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
DRUG CENTRAL
369
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
PUBCHEM
2377
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
MESH
C031906
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
EVMPD
SUB05827MIG
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
CAS
90293-01-9
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
NCI_THESAURUS
C169812
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY
RXCUI
47111
Created by admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
PRIMARY RxNorm
Related Record Type Details
Structure of BIFEMELANE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966